China healthcare firms surge after vaccine waiver plan meets EU resistance


© Reuters. FILE PHOTO: A man wearing a face mask is seen inside the Shanghai Stock Exchange building, as the country is hit by a novel coronavirus outbreak, at the Pudong financial district in Shanghai, China February 28, 2020. REUTERS/Aly Song


SHANGHAI (Reuters) – Shares of Chinese healthcare firms soared on Monday, rebounding from last week’s drubbing after a U.S. proposal to waive patents for COVID-19 vaccines met with fierce opposition from European governments and pharmaceutical giants.

A sub-index tracking health care firms was 1.83% higher at midday, after falling more than 6.8% last week, its worst weekly performance in 10 weeks. That compared with a 0.15% loss for the blue-chip CSI300 index on Monday.

The health care sector received a further boost after Shanghai Fosun Pharmaceutical said on Sunday that a subsidiary has agreed to provide a factory to make up to 1 billion doses annually of the COVID-19 vaccine developed by BioNTech in China.

On Monday, Fosun Pharmacetical’s Shanghai shares soared by the 10% daily limit. Its Hong Kong shares jumped as much as 22.58% higher and were last up 17.78%.

Shanghai shares of CanSino Biologics Inc gained 9.344% and its Hong Kong shares jumped 5.14%

U.S. President Joe Biden backed a proposal last week to waive patent rights on coronavirus vaccines, but his support was rebuffed by European leaders who questioned the usefulness of a waiver and argued that making and sharing vaccines more quickly should take priority.

The European Union, however, is ready to discuss a concrete proposal around vaccine waivers despite scepticism, the chairman of EU leaders said on Saturday.

READ  BAT hikes sales growth outlook amid shift to e-cigarettes

The jump in Chinese vaccine shares also came as analysts downplayed the threat posed by patent waivers.

“The main vaccine threshold is actually more on the production side, and patent liberalisation will not necessarily lead to a large number of mRNA vaccines being copied by companies,” said Wang Ruizhe, an analyst at Capital Securities.

Pfizer-BioNTech and Moderna (NASDAQ:) vaccines use new mRNA technology involving the injection of a small part of the virus’s genetic code (RNA) to stimulate the recipient’s immune response.

Wang said that a strong reaction from U.S. pharmaceutical companies to the waiver proposal meant there were still “variables” around relaxations of vaccine intellectual property.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.


READ  China's Didi aims for 1 million robotaxis on its platform by 2030


Please enter your comment!
Please enter your name here